Lead Product(s) : CAD-9303
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Cowen
Deal Size : $40.0 million
Deal Type : Series B Financing
Cadent Therapeutics Closes $15 Million Final Equity Tranche of Series B Financing
Details : The Company plans to allocate all proceeds to continue development for its lead cognitive disorder asset, CAD-9303 for the treatment of the cognitive deficits and negative symptoms of schizophrenia.
Product Name : CAD-9303
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 29, 2020
Lead Product(s) : CAD-9303
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Cowen
Deal Size : $40.0 million
Deal Type : Series B Financing